Shares of Athenex, Inc. (NASDAQ:ATNX) have received a consensus broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.

Analysts have set a twelve-month consensus price target of $27.50 for the company, according to Zacks. Zacks has also given Athenex an industry rank of 107 out of 265 based on the ratings given to related companies.

A number of brokerages recently commented on ATNX. Laidlaw began coverage on shares of Athenex in a research note on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price objective on the stock. Credit Suisse Group began coverage on shares of Athenex in a research note on Monday, September 18th. They issued an “outperform” rating and a $25.00 price objective on the stock. Royal Bank Of Canada began coverage on shares of Athenex in a research note on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price objective on the stock. Finally, Deutsche Bank AG began coverage on shares of Athenex in a research note on Monday, July 10th. They issued a “buy” rating and a $20.00 price objective on the stock.

TRADEMARK VIOLATION NOTICE: This news story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/25/athenex-inc-atnx-given-27-50-average-target-price-by-brokerages.html.

Athenex (NASDAQ:ATNX) traded up 1.54% during trading on Monday, reaching $17.09. 72,526 shares of the company were exchanged. Athenex has a 12 month low of $11.21 and a 12 month high of $20.79. The stock has a 50 day moving average price of $16.18 and a 200 day moving average price of $16.51. The firm’s market capitalization is $975.21 million.

Athenex (NASDAQ:ATNX) last issued its quarterly earnings data on Monday, August 14th. The company reported ($0.88) EPS for the quarter. The company had revenue of $4.60 million for the quarter. On average, analysts expect that Athenex will post ($2.22) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new stake in Athenex in the 2nd quarter valued at about $240,000. Tudor Investment Corp ET AL acquired a new stake in Athenex in the 2nd quarter valued at about $320,000. Goldman Sachs Group Inc. acquired a new stake in Athenex in the 2nd quarter valued at about $601,000. California Public Employees Retirement System acquired a new stake in Athenex in the 2nd quarter valued at about $800,000. Finally, Vanguard Group Inc. acquired a new stake in Athenex in the 2nd quarter valued at about $800,000. 0.88% of the stock is currently owned by hedge funds and other institutional investors.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Get a free copy of the Zacks research report on Athenex (ATNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Athenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.